摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-5-Methoxy-penten-(2) | 18059-23-9

中文名称
——
中文别名
——
英文名称
cis-5-Methoxy-penten-(2)
英文别名
cis-Penten-(2)-yl-(5)-methylaether;5-methoxy-pent-2c-ene;(Z)-5-methoxypent-2-ene
cis-5-Methoxy-penten-(2)化学式
CAS
18059-23-9
化学式
C6H12O
mdl
——
分子量
100.161
InChiKey
IYFJMSOPJUQBSR-ARJAWSKDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    7
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • THERAPEUTIC SUBSTITUTED PYRROLES
    申请人:Allergan, Inc.
    公开号:US20150336940A1
    公开(公告)日:2015-11-26
    Disclosed herein are compounds of the formula: compositions thereof, and methods for the treatment of glaucoma, reducing intraocular pressure, and other prostaglandin EP 2 mediated disease and disorders.
    本文披露了以下公式的化合物:其组合物以及治疗青光眼、降低眼内压和其他前列腺素EP2介导的疾病和紊乱的方法。
  • Bicyclic acyltryptophanols
    申请人:Bayer Schering Pharma Aktiengesellschaft
    公开号:EP1956016A1
    公开(公告)日:2008-08-13
    The present invention relates to acyltryptophanols of the general formula I, in which Q, V, X, W, R1, R2, R3, R4, R5, R6, R7 and R8 have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.
    本发明涉及通式 I 的酰基色烷醇、 其中 Q、V、X、W、R1、R2、R3、R4、R5、R6、R7 和 R8 的含义如描述中所定义。 根据本发明的化合物是有效的 FSH 拮抗剂,可用于控制男性或女性的生育能力,或用于预防和/或治疗骨质疏松症。
  • NOVEL PYRROLINONE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING SAME
    申请人:Shionogi&Co., Ltd.
    公开号:EP2336109A1
    公开(公告)日:2011-06-22
    The present invention provides a novel P2X3 and/or P2X2/3 receptor antago nist. A compound represented by the formula (I): wherein Z1 is optionally protected hydroxy, etc.; Z2 is -C(=O)-, etc.; Z3a and Z3b are taken together =O or =S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R1a and R1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R2 is substituted or unsubstituted alkyl, etc. R3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
    本发明提供了一种新型 P2X3 和/或 P2X2/3 受体拮抗剂。 由式(I)代表的化合物: 其中 Z1 是任选保护的羟基等;Z2 是-C(=O)-等;Z3a 和 Z3b 合在一起是=O 或=S;t 是 0 至 4 的整数;R4a 和 R4b 各自独立地是氢、取代或未取代的低级烷基等。R1a和R1b各自独立地为卤素、羟基、取代或未取代的低级烷基等;R2为取代或未取代的烷基等;R3为取代或未取代的低级烷基等;R4a和R4b各自独立地为氢、取代或未取代的低级烷基等;R5为取代或未取代的低级烷基等;R6为取代或未取代的低级烷基等;R7为取代或未取代的低级烷基等;R8为取代或未取代的低级烷基等;R9为取代或未取代的低级烷基等;R10为取代或未取代的低级烷基等。R3 是取代或未取代的烷基、取代或未取代的芳基或取代或未取代的杂环基团等;或其药学上可接受的盐或其溶液。
  • IRREVERSIBLE INHIBITORS USEFUL FOR THE TREATMENT OF KINASE-RELATED PATHOLOGIES
    申请人:Winssinger Nicolas
    公开号:US20130053434A1
    公开(公告)日:2013-02-28
    The present invention provides new compounds having a kinase inhibitory activity and useful for treating cancer.
  • US7985765B2
    申请人:——
    公开号:US7985765B2
    公开(公告)日:2011-07-26
查看更多